Trials / Terminated
TerminatedNCT04461600
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
A Phase 2, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Ayala Pharmaceuticals, Inc, · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The current study is designed to evaluate the efficacy and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic TNBC; Notch activation will be determined by a Next Generation Sequencing (NGS) test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL101 | AL101 is an inhibitor of gamma secretase-mediated Notch signaling. |
Timeline
- Start date
- 2020-08-14
- Primary completion
- 2022-03-23
- Completion
- 2022-10-11
- First posted
- 2020-07-08
- Last updated
- 2024-02-12
- Results posted
- 2024-02-12
Locations
29 sites across 5 countries: United States, Belgium, Israel, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04461600. Inclusion in this directory is not an endorsement.